Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study

Matthew D. Miller, Daniel Y. Sze, Siddharth A. Padia, Robert J Lewandowski, Riad Salem, Philani Mpofu, Paul M. Haste, Matthew S. Johnson*

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: To evaluate the effectiveness and safety of yttrium-90 transarterial radioembolization (TARE) for the treatment of primary and metastatic soft tissue sarcoma (STS) of the liver. Materials and Methods: A retrospective review of 39 patients with primary (n = 2) and metastatic (n = 37) hepatic STS treated with TARE at 4 institutions was performed. Fourteen STS subtypes were included, with leiomyosarcoma being the most common (51%). TARE with glass (22 patients) or resin (17 patients) microspheres was performed, with single lobe (17 patients) or bilobar treatment (22 patients) based on disease burden. Adverse events of treatment, overall survival (OS), and tumor response at 3, 6, and 12 months after TARE were assessed per the Response Evaluation Criteria in Solid Tumors. Results: Fourteen patients demonstrated either partial or complete response to therapy, with an objective response rate of 36%. Thirty patients (77%) demonstrated disease control (DC)—either stable disease or response to treatment. Median OS was 30 months (95% confidence interval 12–43 months) for all patients. DC at 3 months was associated with an increased median OS (44 months) compared with progressive disease (PD) (7.5 months; P <.0001). Patients with DC at 6 months also demonstrated an increased median OS (38 months) compared to patients with PD (17 months; P =.0443). Substantial adverse events included 1 liver abscess, 1 gastric ulceration, and 1 pneumonitis. Conclusions: Patients with hepatic STS treated with TARE demonstrated a high rate of DC and a median OS of 30 months, which suggests a role for TARE in the palliation of hepatic STS.

Original languageEnglish (US)
Pages (from-to)867-873
Number of pages7
JournalJournal of Vascular and Interventional Radiology
Volume29
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Yttrium
Sarcoma
Multicenter Studies
Retrospective Studies
Survival
Liver
Therapeutics
Liver Abscess
Leiomyosarcoma
Microspheres
Glass
Pneumonia
Stomach

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Miller, Matthew D. ; Sze, Daniel Y. ; Padia, Siddharth A. ; Lewandowski, Robert J ; Salem, Riad ; Mpofu, Philani ; Haste, Paul M. ; Johnson, Matthew S. / Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma : A Multicenter Retrospective Study. In: Journal of Vascular and Interventional Radiology. 2018 ; Vol. 29, No. 6. pp. 867-873.
@article{1500e6afddc44279b99a3dbffba36772,
title = "Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study",
abstract = "Purpose: To evaluate the effectiveness and safety of yttrium-90 transarterial radioembolization (TARE) for the treatment of primary and metastatic soft tissue sarcoma (STS) of the liver. Materials and Methods: A retrospective review of 39 patients with primary (n = 2) and metastatic (n = 37) hepatic STS treated with TARE at 4 institutions was performed. Fourteen STS subtypes were included, with leiomyosarcoma being the most common (51{\%}). TARE with glass (22 patients) or resin (17 patients) microspheres was performed, with single lobe (17 patients) or bilobar treatment (22 patients) based on disease burden. Adverse events of treatment, overall survival (OS), and tumor response at 3, 6, and 12 months after TARE were assessed per the Response Evaluation Criteria in Solid Tumors. Results: Fourteen patients demonstrated either partial or complete response to therapy, with an objective response rate of 36{\%}. Thirty patients (77{\%}) demonstrated disease control (DC)—either stable disease or response to treatment. Median OS was 30 months (95{\%} confidence interval 12–43 months) for all patients. DC at 3 months was associated with an increased median OS (44 months) compared with progressive disease (PD) (7.5 months; P <.0001). Patients with DC at 6 months also demonstrated an increased median OS (38 months) compared to patients with PD (17 months; P =.0443). Substantial adverse events included 1 liver abscess, 1 gastric ulceration, and 1 pneumonitis. Conclusions: Patients with hepatic STS treated with TARE demonstrated a high rate of DC and a median OS of 30 months, which suggests a role for TARE in the palliation of hepatic STS.",
author = "Miller, {Matthew D.} and Sze, {Daniel Y.} and Padia, {Siddharth A.} and Lewandowski, {Robert J} and Riad Salem and Philani Mpofu and Haste, {Paul M.} and Johnson, {Matthew S.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.jvir.2018.01.775",
language = "English (US)",
volume = "29",
pages = "867--873",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "6",

}

Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma : A Multicenter Retrospective Study. / Miller, Matthew D.; Sze, Daniel Y.; Padia, Siddharth A.; Lewandowski, Robert J; Salem, Riad; Mpofu, Philani; Haste, Paul M.; Johnson, Matthew S.

In: Journal of Vascular and Interventional Radiology, Vol. 29, No. 6, 01.06.2018, p. 867-873.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma

T2 - A Multicenter Retrospective Study

AU - Miller, Matthew D.

AU - Sze, Daniel Y.

AU - Padia, Siddharth A.

AU - Lewandowski, Robert J

AU - Salem, Riad

AU - Mpofu, Philani

AU - Haste, Paul M.

AU - Johnson, Matthew S.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Purpose: To evaluate the effectiveness and safety of yttrium-90 transarterial radioembolization (TARE) for the treatment of primary and metastatic soft tissue sarcoma (STS) of the liver. Materials and Methods: A retrospective review of 39 patients with primary (n = 2) and metastatic (n = 37) hepatic STS treated with TARE at 4 institutions was performed. Fourteen STS subtypes were included, with leiomyosarcoma being the most common (51%). TARE with glass (22 patients) or resin (17 patients) microspheres was performed, with single lobe (17 patients) or bilobar treatment (22 patients) based on disease burden. Adverse events of treatment, overall survival (OS), and tumor response at 3, 6, and 12 months after TARE were assessed per the Response Evaluation Criteria in Solid Tumors. Results: Fourteen patients demonstrated either partial or complete response to therapy, with an objective response rate of 36%. Thirty patients (77%) demonstrated disease control (DC)—either stable disease or response to treatment. Median OS was 30 months (95% confidence interval 12–43 months) for all patients. DC at 3 months was associated with an increased median OS (44 months) compared with progressive disease (PD) (7.5 months; P <.0001). Patients with DC at 6 months also demonstrated an increased median OS (38 months) compared to patients with PD (17 months; P =.0443). Substantial adverse events included 1 liver abscess, 1 gastric ulceration, and 1 pneumonitis. Conclusions: Patients with hepatic STS treated with TARE demonstrated a high rate of DC and a median OS of 30 months, which suggests a role for TARE in the palliation of hepatic STS.

AB - Purpose: To evaluate the effectiveness and safety of yttrium-90 transarterial radioembolization (TARE) for the treatment of primary and metastatic soft tissue sarcoma (STS) of the liver. Materials and Methods: A retrospective review of 39 patients with primary (n = 2) and metastatic (n = 37) hepatic STS treated with TARE at 4 institutions was performed. Fourteen STS subtypes were included, with leiomyosarcoma being the most common (51%). TARE with glass (22 patients) or resin (17 patients) microspheres was performed, with single lobe (17 patients) or bilobar treatment (22 patients) based on disease burden. Adverse events of treatment, overall survival (OS), and tumor response at 3, 6, and 12 months after TARE were assessed per the Response Evaluation Criteria in Solid Tumors. Results: Fourteen patients demonstrated either partial or complete response to therapy, with an objective response rate of 36%. Thirty patients (77%) demonstrated disease control (DC)—either stable disease or response to treatment. Median OS was 30 months (95% confidence interval 12–43 months) for all patients. DC at 3 months was associated with an increased median OS (44 months) compared with progressive disease (PD) (7.5 months; P <.0001). Patients with DC at 6 months also demonstrated an increased median OS (38 months) compared to patients with PD (17 months; P =.0443). Substantial adverse events included 1 liver abscess, 1 gastric ulceration, and 1 pneumonitis. Conclusions: Patients with hepatic STS treated with TARE demonstrated a high rate of DC and a median OS of 30 months, which suggests a role for TARE in the palliation of hepatic STS.

UR - http://www.scopus.com/inward/record.url?scp=85046372362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046372362&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2018.01.775

DO - 10.1016/j.jvir.2018.01.775

M3 - Article

C2 - 29724518

AN - SCOPUS:85046372362

VL - 29

SP - 867

EP - 873

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 6

ER -